Another clinical trial using an attenuated herpes simplex virus type 1, followed by anti-PD-1 therapy for melanoma patients resulted in a 33% complete response rate, with increased CD8+ T cells, and increased PD-L1 protein and IFNγ gene expression in responders. The gene discussed is CD8A; the disease is melanoma.